Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-lipoic acid + insulin
- Development stage
- Phase 3
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Alpha-lipoic acid + insulin is a combination therapy consisting of an antioxidant (alpha-lipoic acid) and a hormone medication (insulin). Alpha-lipoic acid works as an insulin sensitizer by improving glucose uptake via GLUT4 translocation and activation, while also providing antioxidant effects. When combined with insulin, it may enhance glycemic control but requires careful monitoring due to potential hypoglycemic effects.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)INSR (Insulin receptor)
Beyond the preview
Go deeper on alpha-lipoic acid + insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-lipoic acid + insulin.